Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,213.20
(
1.71%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
96.72
(
1.80%
)
Bitcoin
78,238.20
(
0.00%
)
News Focus
News Focus
Post# of 257437
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Double_Bagel post# 190884

Wednesday, 05/06/2015 9:59:44 AM

Wednesday, May 06, 2015 9:59:44 AM

Post# of 257437
ALXN acquires GEVA for $226/sh* in cash and stock:

http://finance.yahoo.com/news/alexion-acquire-synageva-strengthen-global-103900700.html

Alexion Pharmaceuticals, Inc. and Synageva BioPharma Corp. announced today that they have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva…

The $226 figure, which is based on yesterday’s closing price of ALXN, is a 136% premium to GEVA’s closing price yesterday. The nominal deal value is $8.4B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up